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Background: The most common genetic variant of luteinizing hormone (LH), variant-betaLH, has a different
bioactivity than the wildtype. Carrying the variant allele was associated with an increased consumption of
exogenous gonadotropin to achieve optimal ovarian response for in vitro fertilization procedures (IVF). The aim of
this study was to examine if variant-betaLH was also more common in patients with a poor ovarian response to
exogenous gonadotropin which negatively influenced treatment outcome.
Findings: 36 patients with poor ovarian response to ovarian stimulation for IVF and 98 controls with a normal
response were genotyped for variant-betaLH using DNA sequencing. The carrier frequency in the control group
was 17%. No association was found between poor ovarian response and variant-betaLH.
Conclusions: Testing patients for variant-betaLH prior to IVF is unlikely to predict poor ovarian response.
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Background
The most common form of genetically determined vari-
ation in luteinizing hormone (LH) structure is variant-
betaLH (v-betaLH) [1]. v-betaLH is caused by a doublet of
single nucleotide polymorphisms (SNPs) in the LHB gene
that induces a substitution of amino acids (LHB Trp8Arg
and LHB Ile15Thr) in the beta subunit of LH [2]. The
LHB 15Thr introduces an additional glycosylation site to
v-betaLH, probably affecting the serum half-life of LH and
thereby its bioactivity [3-5]. Various physiological and clin-
ical implications of v-betaLH were proposed, including in-
fertility and premature ovarian failure [6,7]. In the field of
in vitro fertilization (IVF), patients who required an in-
creased amount of recombinant follicular stimulating hor-
mone (rFSH) to achieve an optimal ovarian response in
controlled ovarian hyperstimulation (COH) were classified
as hypo-responders [8]. Alviggi and co-workers reported
that v-betaLH was more common in hypo-responders in a
series of 60 Italian IVF patients [9]. This finding was* Correspondence: Hans.Ivar.Hanevik@sthf.no
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unless otherwise stated.recently confirmed in a larger series of Danish IVF patients
[8], and is of interest when searching for genetic predictors
of ovarian response to COH [10]. Poor ovarian response
(POR) has similarities to hypo-response, but is more ad-
verse for the patient’s treatment outcome [11]. Patients with
POR have a markedly decreased chance of pregnancy from
IVF treatment [12], whereas hypo-responders by definition
achieve an optimal ovarian response [8]. The aim of the
present study was to investigate if v-betaLH was more
common in IVF patients with POR. If so, this would
strengthen the case raised by Alviggi and co-workers for
determining v-betaLH status in patients prior to COH [8].
Methods
Patients
Genomic DNA from 134 IVF patients was obtained from
a preexisting biobank established to study genetic predic-
tors of COH. Background data and data on other putative
genetic predictors for ovarian response to COH in these
patients were already published together with further de-
tails on patient recruitment and selection [13-18]. In brief
all patients undergoing COH at Fertilitetsklinikken Sør
from January 2003 to June 2009 were eligible for participa-
tion in the biobank. By feeding the criteria shown inl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ively classified as having had a normal or poor ovarian re-
sponse. The potential participants’ patient files were then
checked manually for accuracy of information in the data-
base, and a total of 338 patients were asked to contribute
to the biobank by signing a consent form and delivering a
blood sample. For all patients in the present study COH
was by gonadotropic releasing hormone (GnRH) agonist
mid luteal phase down regulation and rFSH (Puregon®,
Merck, NJ, USA or Gonal-F®, Merck-Serono, Geneva,
Switzerland). The standard starting dose of rFSH was
150 IU/day. Patients who were judged by clinicians to be at
risk for POR had their starting dose adjusted without any
specific standard of adjustment. During COH the ovarian
response to COH was evaluated by ultrasound, and the
dose of gonadotropin adjusted if necessary. Ovulation in-
duction was by injection of urine-based or recombinant hu-
man chorionic gonadotropin (hCG) when at least one
follicle had a mean diameter of 17 mm. Oocyte retrieval
took place 34–36 hours after hCG injection. Available for
the present study were 36 POR patients, and 98 controls
with a normal ovarian response to COH.
Genotyping
Genotyping was done by DNA sequencing. Genomic
DNA was isolated from peripheral blood according to
standard procedures using EZ1 BioRobot (QIAGEN) and
stored at −20°C. Each PCR-reaction contained 50 ng of
genomic DNA, 0.20 M of each primer, 1x AccuPrime PCR
buffer II (Invitrogen), 0.60 U AccuPrime Taq DNA poly-
merase (Invitrogen) and milliQ H2O to a final volume of
12.5 l. Primer sequences used: LHB F 5′-GGG TGA AGC
AGT GTC CTT GT-3′ and LHB R 5′-GAA GAG GAG
GCC TGA GAG TT-3′ [2]. Cycling conditions were: 95C
for 5 min, then 35 cycles of 95C for 30 s, 65C for 30 s and
72C for 30 s, then 72C for 10 min, then 4C ∞. The
primers amplified most of exon 2 and 3 of LHB and gave aTable 1 Inclusion- and exclusion criteria
Poor ovarian
Inclusion-criteria:
IU of rFSH per day 150-20
No. of oocytes obtained by oocyte retrieval ≤ 3
Exclusion-criteria:
IU of rFSH per day < 150 or >






Ovarian cystsspecific PCR-product excluding the homologous CGB
genes (verified by gel electrophoresis and blast of sequence).
The PCR-products were sequenced in both directions using
BigDye Terminator kit v.3.1 (Applied Biosystems) and an
ABI3130xl Genetic Analyzer (Applied Biosystems) accord-
ing to the manufacturer’s procedures. The sequences were
aligned to LHB RefSeq NG_011464.1 [19] using SeqScape
v.2.6 software (Applied Biosystems). Samples were ana-
lysed in the order they arrived at the lab, often giving sam-
ples from both groups of patients in each run. Repeated
sequencing of a random 16% subset yielded 100% identical
sequences.
Statistics
Sample size was limited to 36 cases and 98 controls by the
study-design. Chi-square statistics were used for compari-
son of carrier and allele frequency of v-betaLH. Prior data
indicated that the carrier frequency among controls was
0.11 [8]. If the true carrier frequency among cases was
threefold, 0.33, then the null hypothesis that the carrier
frequency for cases and controls were equal would be
rejected with probability (power) 0.82 [20]. Other compar-
isons between groups were by student’s t-test or chi-
square. For all comparisons differences between groups
were considered statistically significant if reaching a p-
value of <0.05.Results
Table 2 shows the clinical and genetic data for the two
groups. The background data included in the table were
already published [13-18]. LHB Trp8Arg and LHB
Ile15Thr were in complete linkage disequilibrium and
were denominated v-betaLH. There were no significant
differences in carrier frequency or allelic frequency of v-
betaLH between groups. The only homozygous carrier
was in the control group.response Controls
0 150-200
5-13
200 <150 or > 200
ars > 40 years
syndrome As for poor ovarian response.
al surgery Present or previous signs of moderate or





Table 2 Clinical and genetic data
Characteristic Poor ovarian response (n = 36) Controls (n = 98)
Age mean (95% CI) 34.0b (32.8-35.3) 32.4 (31.9-32.8)
BMI (kg/m2) mean (95% CI) 26.5b (24.3-28.7) 23.8 (23.1-24.5)
No. of patients of other ethnicities than Caucasian (%) 3 (8.3) 4 (4.1)
First time COH (%) 32 (88.9) 83 (84.7)
Early follicular phase s-FSHa mean (95% CI) 6.0 (5.3-6.7) 5.8 (5.4-6.3)
First dose of rFSH (IU) mean (95% CI) 160 (152–168) 159 (155–162)
Duration of rFSH medication (Days) mean (95% CI) 10.8 (10.2-11.3) 10.9 (10.8-11.1)
Total dose of rFSH (IU) mean (95% CI) 1739 (1616–1863) 1738 (1692–1784)
Oocytes retrieved mean (95% CI) 1.5b (1.1-2.0) 9.0 (8.5-9.5)
No. of embryos transferred mean (95% CI) 0.6b (0.4-0.9) 1.6 (1.5-1.7)
Live births (% of started COH) 2b (6) 45 (46)
No. of patients with v-betaLH (%) 4 (11) 17 (17)
No. of alleles with v-betaLH (%) 4 (6) 18 (9)
aNot registered for all patients. N registered for the respective groups: 32, 76.
bStatistically significant (p-value of <0.05) difference compared to controls by student’s t-test or chi square.
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The present data are, to our knowledge, the first to esti-
mate the prevalence of v-betaLH in a Norwegian popula-
tion. A carrier frequency of 17% amongst normal
responders to COH in an IVF population is comparable to
11% in a similar Danish IVF population [8]. In unselected
populations a wide variation of v-betaLH carrier frequency
was reported ranging from 42% in Finnish Lapps through
19% in Swedes to 7% in Hispanics in the USA [1]. No as-
sociation was found between POR and v-betaLH in this
study. This finding is in accordance with the only reported
genome wide association study concerning ovarian re-
sponse to COH [21]. Alviggi and co-workers [8] suggested
that IVF patients with v-betaLH lack sufficient LH activity
to adequately support FSH activity in multiple follicular
development, leading to hypo-response to COH as defined
above. The present results suggest that the decreased
ovarian response in POR patients may require a different
explanation, and point to the question of whether ovarian
response to COH declines gradually from normal via hypo
to poor, or if the three should be considered separate situ-
ations altogether [22]. The hypothesis proposed by Alviggi
and co-workers [8], that carriers of v-betaLH could benefit
from exogenous LH in their COH, seems unlikely to apply
to POR patients from the present results; however, a dif-
ferent study design is required to test this properly.
Differences in numbers of oocytes retrieved, embryos
transferred and live births were as expected from the
inclusion- and exclusion criteria. There were no differ-
ences between groups regarding the FSH receptor SNPs
reported to influence ovarian response to COH (data not
shown). The control group was also not matched to the
POR group, leading to differences in age and BMI between
groups. Albeit small, these differences are a possibleconfounder in the study inasmuch as BMI was reported to
influence ovarian response to COH [23] and the risk of
POR increases with age [11]. The use of rFSH was similar
between groups, reflecting that POR was unexpected by
clinicians for the patients in the POR-group.
All COHs in this study, as in the studies by Alviggi and
co-workers [8,9], were by GnRH agonist mid luteal phase
down regulation. Whether v-betaLH is associated with
hypo-response or POR in an antagonist protocol is un-
known. However, the low endogenous level of LH in agon-
ist cycles could arguably make v-betaLH more influential
in agonist than antagonist cycles.
Genotype data from the same patients regarding other
signaling systems of importance in ovarian physiology
and their association with ovarian response to COH
were presented earlier [13-18]. This raises the question
of multiple testing in genetic association studies. How-
ever, as the present study showed negative results, con-
cerns over false positive findings were unwarranted.
The present study had two main limitations; sample size
and inclusion criteria. The above sample size calculations
show that the study had adequate power to find a difference
between groups if v-betaLH prevalence was three times
higher in the POR group than in controls. A study with
more patients could have detected smaller differences be-
tween groups. However, to avoid a high rate of false nega-
tives when applying v-betaLH as a predictor of POR, a high
prevalence of v-betaLH in the POR group is required.
The inclusion criteria for POR patients did not comply
with ESHRE’s Bologna criteria [11]. The criteria for POR
found in Table 1 were set to identify patients in which POR
came unexpectedly, as it is in these patients that novel pre-
dictors of ovarian response could be most useful. Also the
criteria in Table 1 assured that the patients included had
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response to COH apart from the putative genetic ones such
as v-betaLH. The Bologna criteria on the other hand have
‘advanced maternal age’ and ‘previous POR’, as two of three
criteria for POR, making them inadequate for identification
of patients with an unexpected poor response, at least
retrospectively as done in this study.
Other limitations in the present study were unavail-
ability of s-LH measurements prior to and during COH,
and no data on s-AMH or antral follicle count to predict
ovarian response to COH.
Conclusions
In conclusion this study found no association between
v-betaLH and unexpected POR. This indicates that it is
unlikely that testing IVF patients for v-betaLH prior to
COH would contribute to predicting POR.
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